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Abstract
Background: The aim of this study was to evaluate the diagnostic value of the asphericity (ASP) as a novel
quantitative parameter, reflecting the spatial heterogeneity of tracer uptake, in the staging process of patients with
68Ga-PSMA-HBED-CC positron emission tomography (PET)-positive prostate cancer (PC).
In this study, 37 patients (median age 72 years, range 52–82 years) with newly diagnosed PC, who received a
68Ga-PSMA-HBED-CC PET fused with computed tomography (68Ga-PSMA-PET/CT), a magnetic resonance imaging
(MRI) of the prostate, and a core needle biopsy (within 74.2 ± 80.2 days) with an available Gleason score (GSc)
were extracted from the local database. The ASP and the viable tumor volume (VTV) was calculated using the
rover software (ABX GmbH, Radeberg, Germany), a segmentation tool for automated tumor volume delineation.
Additionally, parameters including total lesion binding rate (TLB), maximum, mean and peak standardized uptake
value (SUVmax/mean/peak), prostate-specific antigen (PSA), D’Amico classification, and prostate imaging
reporting and data system (PI-RADS) were analyzed.
Results: The ASP mean differed significantly (p ≤ 0.05) between the different GSc groups: GSc 6–7: 11.9 ± 4.8%,
GSc 8: 25.5 ± 4.8%, GSc 9–10: 33.3 ± 6.8%. A significant correlation between ASP and GSc (rho = 0.88; CI 0.78–0.94;
p < 0.05) was measured. The ASP enabled an independent (p > 0.05) prediction of the GSc. A moderate correlation
was measured between ASP and the D’Amico classification (rho = 0.6; CI 0.32–0.78; p < 0.05). The VTV showed a
moderate correlation with the SUVmax (rho = 0.58; CI 0.32–0.76; p < 0.05) and the GSc (rho = 0.51; CI 0.23–0.72; p < 0.05).
Conclusion: The asphericity in 68Ga-PSMA-PET could represent a promising novel quantitative parameter for an improved
non-invasive tumor staging of patients with PC.
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Background
Prostate cancer (PC) is the most frequent cancer entity
diagnosed in men in the western world with the second
highest overall mortality [1]. PC is responsible for up to
8% of all cancer-related deaths in males, resulting in the
fourth leading cause of cancer-related death in both
sexes [1]. The prostate-specific antigen (PSA) blood level
is currently the reference standard for PC screening of
the population. With a risk reduction of 1.07 deaths per
1000 cases, PSA screening was shown to reduce PC-
associated mortality up to 21% [2]. However, it is not
fully elucidated to which extent PSA reduces the all-
cause PC-associated mortality [2]. Besides the positive
effects of PSA screening, PSA testing can also be associ-
ated with an overdiagnosis of up to 23–42% [3, 4]. While
advances, especially in the non-invasive local staging of
patients with primary PC, have been made using mag-
netic resonance imaging (MRI) in recent years, this tech-
nique is still associated with limitations regarding the
grading of the primary tumor [5].
To improve the local and whole body staging of
patients with PC, different nuclear imaging probes were
evaluated in recent years [6]. These include tracers based
on N-methyl-11C-choline (11C-C) or 18F-fluoromethyl-
[1,2-2H4]choline (18F-C), 11C-acetate, 2-amino-4-11C-
methylsulfanyl-butanoic acid, 1-S-methyl-11C-methionine
(11C-MET), 18F-fluorodihydrotestosterone (18F-FDHT), and
2-deoxy-2-18F-fluoro-D-glucose (18F-FDG) [7]. These
tracers are not commonly used in clinical practice, as they
have a limited sensitivity and specificity in staging of
PC [6–11]. A recently introduced novel tracer, the
68Ga-N,N-bis[2-hydroxy-5-(carboxyethyl)benzyl]-ethy-
lendiamine-N,N diacetic acid-labeled prostate-specific
membrane antigen (PSMA) inhibitor Glu-NH-CO-NH-
Lys(Ahx)-HBED-CC (68Ga-PSMA-HBED-CC), has shown
promise to improve the local and whole-body staging of
patients with PC [12]. 68Ga-PSMA-HBED-CC demon-
strates a strong affinity to the prostate-specific membrane
antigen and showed promising results in diagnosing re-
current PC, even at low PSA blood levels, and was found
to be superior to standard routine imaging for preopera-
tive lymph node staging in primary PC patients [13, 14].
Most current studies, which investigate positron emis-
sion tomography (PET) tracer uptake in different malig-
nancies, rely on the maximum standardized uptake
value (SUVmax) as a quantitative parameter for the
characterization of the binding/uptake of the tracer.
However, it is increasingly recognized that not only the
overall uptake or metabolism, but also the heterogeneity
of the tracer uptake, plays a role in the characterization of
malignancies [15–18]. The quantification of the hetero-
geneity of tracer uptake could represent a promising novel
parameter for an improved characterization of tumor
heterogeneiety and therefore the malignancy of tumors
[19]. In this context, a novel parameter—the asphericity
(ASP)—was recently introduced [15]. The ASP describes
the non-spherical shape of a tumor, compared to a
sphere with the same volume. Initially, the ASP was
used to quantify the spatial irregularity of the metabolic
tumor volume (MTV) in 18F-FDG-PET [15, 18–21].
Most tumors are genetically and histopathologically
heterogenic and further dedifferentiation and infiltration
is often associated with poorer prognosis [15]. Previous
studies demonstrated the potential of the ASP for an im-
proved tumor staging [15, 19].
The aim of this study was to test the diagnostic





This retrospective study was approved by the local ethics
review board. The local database was screened for pa-
tients, who received a 68Ga-PSMA-PET combined with
computed tomography (CT) and a 3 T MRI of the pros-
tate within 110 days for staging of suspected primary
PC. MRI was used as reference standard for the defin-
ition of the primary tumor and to evaluate our delinea-
tion process. The proximity of the 68Ga-PSMA PET/CT
to the MRI was a requirement to ensure that the lesion
which was evaluated in 68Ga-PSMA PET reflects the
primary PC lesion. We extracted 691 patients from our
imaging database, who underwent 68Ga-PSMA-PET/CT
in-between Oct. 01, 2013 and Feb. 01, 2017. MRI data of
the prostate was available in 169 cases, excluding 522
cases without a MRI of the prostate. In our institution,
3 T MRI has established itself as the routine MR exam-
ination for the evaluation of patients with prostate can-
cer. Twenty-six cases were excluded as only 1.5 T MRI
datasets were available. Ninety patients were excluded as
the delay between 68Ga-PSMA-PET/CT and 3 T MRI
was more than 110 days. All PSMA-positive lesions had
to be confirmed through core needle biopsy, which was
not available for this study in 16 patients. The final co-
hort of 37 patients had a mean age of 71.3 ± 7.5 years
and received both scans within 50.2 ± 32.5 days. Core
needle biopsy and 68Ga-PSMA-PET/CT were per-
formed within 74.2 ± 80.2 days. A detailed overview
regarding the patient characteristics are summarized in
Table 1.
Positron emission tomography tracer
Elution of 68Ga was performed using a standard
68Ge/68Ga generator (Eckert and Ziegler) [22]. Next,
PSMA-HBED-CC (ABX GmbH, Radeberg, Germany)
was labeled with 68Ga [23, 24].
Meißner et al. EJNMMI Research  (2017) 7:85 Page 2 of 12
Imaging protocol
PET/CT imaging was performed 75.4 ± 27.5 min after
intravenous injection of 122.4 ± 19.7 MBq of [68Ga]-
PSMA-HBED-CC. A 3D acquisition mode was used on
a Gemini TF 16 Astonish PET/CT scanner (Philips
Medical Systems) [25]. Default parameter settings were
used in the system software to reconstruct the transaxial
slices (144 × 144 voxels, 4 mm3). Immediately before the
PET scan, a low-dose CT was acquired for attenuation
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ASP is defined as a marker for non-spherical tumor vol-
umes. A sphere has the smallest possible surface S for a
given volume V for which ASP = 0 by definition [15].
For non-spherical lesions, ASP > 0 provides a quantita-
tive measure for deviation of spherical shape. For ex-
ample, an ASP of 30% means a 30% larger surface than a
sphere with the same volume [19]. A detailed descrip-
tion of the definition was published earlier [15].
Imaging analysis
The program Visage 7.1 (Visage Imaging) was used prior
to the delineation process for evaluation of the 68Ga-
PSMA-PET/CT and the MRI data. In case of multiple
foci or lesions with unclear borders in PET, a simultan-
eous evaluation of the MRI data in Visage 7.1 supported
the detection/delineation of the primary PC lesion.
Following the detection of the primary lesion within the
prostate using the rover software (ABX GmbH,
Radeberg, Germany), a 3D mask was placed around the
volume of interest (VOI). Rover uses a specific algorithm
that delineates the tumor automatically. This is achieved
by adaptive thresholding and taking the background sig-
nal of the surrounding tissue into account [20]. In some
cases, the strong radiotracer signal from the bladder was
interfering with a fully automatic delineation of the
tumor. Therefore, the tumor delineation was inspected
in axial, coronal, and sagittal planes in all cases and the
VOIs were corrected manually, if necessary. Computed
parameters of the VOIs included the ASP, SUVmax,
SUVmean, SUVpeak and the viable tumor volume
(VTV). Figures 1 and 2 show examples of the delinea-
tion of the tumor using the rover software in patients
with different Gleason scores (GSc).
Viable tumor volume and tumor lesion binding rate
Accumulation of 68Ga-PSMA-HBED-CC in PC cells
depends on the PSMA expression on the cell surface.
PSMA is highly overexpressed in PC cells, resulting in a
strong signal in PET [26]. The accumulation of 68Ga-
PSMA-HBED-CC is reduced in non-diseased prostate
tissue, expressing lower PSMA levels on their cell sur-
face. This leads to a delineation of a VTV, at the location
at which 68Ga-PSMA-HBED-CC internalization is highly
active. Derived from the “total lesion glycolysis” used in
18F-FDG-PET/CT, a further parameter used in this study
was the “total lesion binding” rate (TLB). The TLB was
defined as the product of the SUVmean and the VTV of
a PC lesion.
Gleason score
All 37 patients underwent core needle biopsy of the
prostate for a histopathological characterization of
tumor malignancy. The GSc takes into account that ma-
lignancy signs such as cell size, nucleus size, nucleus to
cytosol ratio, abnormal mitosis, and necrosis affect the
grading. The final score is an addition of the most com-
mon found tumor grade and the highest found tumor
grade for all tissue samples [27].
TNM and D’Amico classification
TNM is a clinical used score for staging, for determin-
ation of prognosis and treatment planning. T-Stage
describes the tumor size and tumor infiltration in sur-
rounding tissue. N-stage indicates the presence of lymph
node metastases; M-stage describes the presence of re-
mote metastases outside the prostate [28].
The risk stratification for progression of PC can be mea-
sured with the D’Amico classification tool. It takes PSA
blood level, clinical tumor size (through endorectal exam-
ination), and GSc (core needle biopsy) into account. It
classifies patients according to low, intermediate, or high
Table 1 Characteristics of study collective
Mean SD Median Range
Age (years) 71.3 7.5 72 52–82
Days PSMA-PET to MRI 50.2 32.5 42 1–110
PI-RADS score 4.7 0.6 5 3–5
Days GSc to PSMA-PET 74.2 80.2 46 3–299
Gleason score 7.9 1.1 8 6–10
Days PSA to PSMA-PET 16.2 25.6 3 0–84
PSA (ng/ml) 17.7 21.5 11 0.23–116
VTV (cm3) 12.3 11.3 9 0.8–54.1
This table summarizes the main characteristics of the patients investigated in
this study. This included the age of the patients, the PI-RADS and Gleason
score, PSA blood level, and the viable tumor volume as well as the time
difference between PSMA-PET and MRI, between Gleason score and PSMA-PET,
between PSA blood level sampling date and PSMA-PET. Data are given in means,
standard deviations, medians, and ranges. Abbreviations: GSc Gleason score, PSA
prostate-specific antigen blood level, PSMA prostate-specific membrane antigen,
PET positron emission tomography, MRI magnetic resonance imaging, PI-RADS
prostate imaging reporting and data system, VTV viable tumor volume
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risk for early metastasis and increased tumor aggres-
siveness [29].
Prostate imaging reporting and data system
Prostate imaging reporting and data system (PI-RADS)
is a score used for standardized reporting of clinical
findings in magnetic resonance imaging examinations of
the prostate. In 2014, an update towards version 2 was
released. MRI sequences included in PI-RADS v2 evalu-
ation, which was used for all patients in this study, are
high-resolution T2-weighted imaging, diffusion-weighted
imaging, and dynamic contrast-enhanced imaging
Fig. 1 Example of tumor heterogeneity for the asphericity assessment in a patient diagnosed with a Gleason score 6 prostate cancer. A–D Example of
a patient diagnosed with a Gleason score 6 prostate cancer in the right peripheral zone of the apex of the prostate. A, B Corresponding orientations
(transversal (A1), coronal (A2), and sagittal (A3)) are shown for 68Gallium-labeled prostate-specific membrane antigen positron emission tomography,
fused with computed tomography (B1–3). Based on positron emission tomography, an avid tumor was delineated in all three planes using the rover
software. C, D Corresponding magnetic resonance imaging in the high-resolution T2 turbo spin echo (C) and diffusion-weighted images (D) in axial
images confirm the presence of the malignant lesion at the respective location. HR: high-resolution, DWI: diffusion-weighted imaging
Fig. 2 Example of tumor heterogeneity for the asphericity assessment in a patient diagnosed with a Gleason score 9 prostate cancer. A–D Example of
a patient diagnosed with a Gleason score 9 prostate cancer in the in the right peripheral zone of the midgland of the prostate. A, B Corresponding
orientations (transversal (A1), coronal (A2), and sagittal (A3)) are shown for 68Gallium-labeled prostate-specific membrane antigen positron emission
tomography, fused with computed tomography (B1–3). Based on positron emission tomography, an avid heterogeneous tumor was delineated in all
three planes using the rover software. C, D Corresponding magnetic resonance imaging in T2 turbo spin echo (C) and diffusion-weighted images
(D) in axial images confirm the presence of the maligne lesion at the respective location. HR: high-resolution, DWI: diffusion-weighted imaging
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sequences. For each sequence, a score of 0–5 indicates
the probability of a clinical significant PC lesion leading
from improbable to highly suspicious in score 5. Every
lesion is scored in the three sequences resulting in three
sub-scores. The resulting final PI-RADS score is a sum-
marized score [30, 31].
Standardized uptake value
The SUV is a degree of tracer uptake in a specific region
of interest (ROI) or VOI. It is calculated as the product
of the activity concentration (Bq/g) and the patient’s
weight (g) divided through the applied dose (Bq). SUV-
max, SUVmean, and SUVpeak can be calculated for every
ROI or VOI [32]. In addition to maximum and mean
SUV, SUVpeak was computed as the mean value of a 3D
sphere with a diameter of approximately 1.2 cm centered
at the VOI maximum. All parameters were computed
using the rover software.
Statistical analysis
Descriptive statistics, correlations, and scatter plots were
computed using MedCalc Statistical Software version
17.2 (MedCalc Software bvba, Ostend, Belgium;
http://www.medcalc.org; 2017). All univariate correla-
tions including ordinal variables were tested using
Spearman’s rank correlation method. Pearson’s correlation
method was used for metric variables. A p value < 0.05
was considered statistically significant. The polytomous
universal model implemented in the statistic software
IBM SPSS (version 24) was used for the ordinal logistic re-
gression. Ordinal regression models the propensity of the
first ranked state against all higher ranked states. This is
repeated for the second and ongoing ranked states result-
ing in k–1 intercept parameters for k ordinal levels. We
included the independent variables ASP, VTV, and TLB in
the model. Ordinal regression is preferable, when the out-
come consists of several discrete but ordered states in-
stead of the assumption of a continuous dependent
variable in linear regression. The group-based analysis for
GSc was tested using Bonferroni corrected t-tests in SPSS.
ASP probability was visualized using R software
(Version 3.2.5, Vienna, Austria, http://www.R-project.org).
Variables are reported as mean as well as standard devi-
ation (SD).
Results
Association of asphericity with histopathology
Patients in this study demonstrated GSc ranging from 6
to 10 with a median of 8. Computing of ASP resulted in
an overall mean 23.2 ± 10.1% ranging from 5 to 46.5%
(CI 19.8–26.5). A close correlation was found between
ASP and GSc (rho = 0.88; p < 0.05; CI 0.78–0.94).
Twelve patients with GSc of 6–7 demonstrated an aver-
age ASP of 11.9 ± 4.8% (range 5.0–18.6%). Fifteen
patients with GSc of 8 demonstrated an average ASP of
25.5 ± 4.8% (range 18.9–33.9%). Ten patients with GSc
of 9–10 demonstrated an average ASP of 33.3 ± 6.8%
(range 20.8–46.5%). Group-based analysis showed sig-
nificant (p < 0.05) differences in ASP levels for Gleason
6–7 vs. Gleason 8 and for Gleason 8 vs. Gleason 9–10.
The bar chart in Fig. 3 demonstrates the subgroup ana-
lysis. The scatter plot shows the regression with the as-
sociated 95% confidence interval. The correlation was
shown to be significant (R2 = 0.84, p < 0.05).
Probability of Gleason score based on asphericity
Ordinal logistic regression computed statistically signifi-
cant (p < 0.05) effects to predict GSc based on given
ASP. Threshold ASP values were computed, for the dif-
ferentiation of the different GSc. Threshold values for a
change from subgroup Gleason 6–7 to Gleason 8 was
computed at an ASP of 5.6% (CI 7.3–29.2%) and prob-
able change from subgroup Gleason 8 to Gleason 9–10
at an ASP of 30.4% (CI 13.2–48.9%). Grouped ranges
were 0–5.6% for Gleason 6–7, 5.6–30.4% for Gleason 8
and ≥ 30.4% for Gleason 9–10. These results are summa-
rized in Fig. 4.
Association of asphericity with D’Amico classification,
N-stage, and PI-RADS score
ASP and D’Amico classification showed a moderate cor-
relation (rho = 0.6; p < 0.05; CI 0.32–0.78). Low risk pre-
sented an ASP of 5.0%, intermediate risk demonstrated
an average ASP of 15.2 ± 2.1% (range 11.7–17.1%), and
high risk presented an average ASP of 27.2 ± 8.5%
(range 5.2–46.5%). No significant (p > 0.05) correlation
was measured between ASP and N-stage (rho = − 0.07;
p > 0.05; CI − 0.51–0.4). Additionally, a non-significant
(p > 0.05) weak correlation was seen between ASP and the
PI-RADS score (rho = 0.26; p > 0.05; CI − 0.11–0.57). All
results are summarized in Table 2.
Association of viable tumor volume with Gleason score,
D’Amico classification, N-stage, and PI-RADS score
The study cohort presented an average VTV of
12.3 ± 11.3 cm3 ranging from 0.8 to 54.1 cm3 and a
moderate correlation could be demonstrated for VTV
and GSc (rho = 0.51; p < 0.05; CI 0.23–0.72). VTV aver-
ages for GSc 6 were 6.1 ± 7.6 cm3 (range 0.8–17.3 cm3);
for GSc 7, 7.5 ± 6.8 cm3 (range 2.3–23.6 cm3); for GSc
8, 11.4 ± 12.5 cm3 (range 2.9–54.1 cm3); for GSc 9,
23.0 ± 9.0 cm3 (range 10.8–39.1 cm3); and for GSc 10,
7.8 ± 6.7 cm3 (range 3–12.5 cm3). VTV presented a
moderate association to the respective D’Amico classifi-
cation (rho = 0.49; p < 0.05; CI 0.17–0.71). VTV was
3.9 cm3 for low risk; intermediate risk scored patients
showed an average VTV of 4.7 ± 2.5 cm3 (range 2.3–
8.9 cm3). Patients scored with high risk of progression
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demonstrated an average VTV of 14.6 ± 11.9 cm3 (range
2.9–54.1 cm). No significant (p > 0.05) correlation was
found for VTV to N-stage (rho = − 0.06; p > 0.05; CI −
0.5–0.4). VTV presented a non-significant (p > 0.05) weak
correlation to the PI-RADS score (rho = 0.33;
p > 0.05; CI − 0.04–0.62). All results are summarized
in Table 2.
Association of total lesion binding rate with Gleason
score, D’Amico classification, N-stage, and PI-RADS score
TLB presented an average of 99.2 ± 136.3 ranging be-
tween 3 and 584.3 showing statistical significant
(p < 0.05) weak correlations to GSc (rho = 0.43;
p < 0.05; CI 0.12–0.66) and to D’Amico classification
(rho = 0.38; p < 0.05; CI 0.04–0.64). No correlation
was found towards N-stage (rho = 0; p > 0.05; CI −
0.45–0.45) and a non-significant (p < 0.05) weak cor-
relation was seen for TLB to the PI-RADS score
(rho = 0.3; p > 0.05; CI − 0.07–0.6). All results are
summarized in Table 2.
Association of maximum, peak and mean standardized
uptake values with Gleason score, D’Amico classification,
N-stage, and PI-RADS score
SUVmax of all PC lesions presented an average of
18.1 ± 19.4 ranging between 3.3 and 83.2 and demon-
strated non-significant (p > 0.05) weak correlations to
GSc (rho = 0.29; p > 0.05; CI − 0.04–0.56) and D’Amico
classification (rho = 0.29; p > 0.05; CI − 0.06–0.58). A
non-significant (p > 0.05) very weak negative association
was seen for SUVmax to N-stage (rho = − 0.14; p > 0.05;
CI − 0.56–0.33) and a non-significant (p > 0.05) weak
correlation towards PI-RADS score (rho = 0.22; p > 0.05;
CI − 0.15–0.54). With an average of 6.1 ± 3.2 ranging be-
tween 2.2 and 16.8, SUVmean presented comparable
non-significant (p > 0.05) weak to very weak correlations
to GSc (rho = 0.24; p > 0.05; CI − 0.09–0.53), D’Amico
classification (rho = 0.2; p > 0.05; CI − 0.15–0.51),
N-stage (rho = 0.13; p > 0.05; CI − 0.35–0.55), and
PI-RADS score (rho = 0.1; p > 0.05; CI − 0.27–0.44).
SUVpeak presented an average of 15.3 ± 15.9 ranging be-
tween 3.1 and 76.4 with non-significant (p > 0.05) weak
correlations to GSc (rho = 0.3; p > 0.05; CI − 0.03–0.57)
and D’Amico classification (rho = 0.3; p > 0.05; CI − 0.05–
0.58). No correlation was seen towards N-stage
(rho = − 0.05; p > 0.05; CI − 0.49–0.42) and a non-
significant (p > 0.05) very weak correlation to PI-RADS
score (rho = 0.13; p > 0.05; CI − 0.24–0.47). All results are
summarized in Table 2.
Association of prostate-specific antigen blood level with
Gleason score, D’Amico classification, N-stage, and
PI-RADS score
PSA blood samples were taken in mean 16.2 ± 25.6 days
ranging 0 to 84 days and demonstrated an average of
17.7 ± 21.5 ng/ml ranging 0.23 to 116 ng/ml. PSA showed
non-significant (p > 0.05) weak to very weak correlations
to GSc (rho = 0.27; p > 0.05; CI − 0.06–0.55) and to
D’Amico classification (rho = 0.15; p > 0.05; CI − 0.21–
0.47). Additionally, no correlation was seen for PSA to N-
stage (rho = 0.07; p > 0.05; CI − 0.4–0.51) and a weak
non-significant (p > 0.05) correlation to PI-RADS score
(rho = 0.12; p > 0.05; CI − 0.25–0.46). All results are sum-
marized in Table 2.
Fig. 3 Differences between the asphericity for prostate cancer lesions with a Gleason score of 6–7, 8, and 9–10. a The bar chart demonstrates the
asphericity values for the different Gleason score subgroups. A significant difference (p ≤ 0.05) was measured between prostate cancer lesions
with a Gleason score of 6–7 and 8 and lesions with a Gleason score of 8 and 9–10. This potentially indicates that an increased tumor dedifferentiation/
heterogeneity is accompanied by a gradual rise in the asphericity. Error bars indicate standard deviations. b The scatter diagram presents the
correlation of the asphericity towards the Gleason scores. The linear regression line and the 95% confidence interval is shown. ASP: asphericity
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Prognostic estimation of Gleason scores using asphericity,
viable tumor volume, and total lesion binding rate on
multivariable analysis
On multivariable analysis regarding independent associ-
ation of ASP, VTV, and TLB with the GSc, the ASP and
the VTV represented independent predictive parameters
(0.71; CI 0.35–1.06 and 0.36; CI 0.03–0.69). The TLB did
not represent an independent parameter (− 0.02; CI −
0.04–0.004). All variables are summarized in Table 3.
Association of maximum, peak and mean standardized
uptake values and prostate-specific antigen blood level with
asphericity, viable tumor volume, and total lesion binding
rate
SUVmax demonstrated a weak non-significant (p > 0.05)
correlation to the ASP (rho = 0.23; p > 0.05; CI − 0.1–0.51)
and statistically significant (p < 0.05) moderate correlations
to VTV (rho = 0.58; p < 0.05; CI 0.32–0.76) and TLB
(rho = 0.71; p < 0.05; CI 0.5–0.84). As expected, SUVmean
and SUVpeak did show comparable associations as seen
for SUVmax. SUVmean presented a non-significant
(p > 0.05) weak correlation to the ASP (rho = 0.17;
p > 0.05; CI − 0.17–0.47), and moderate correlations to
VTV (rho = 0.68; p < 0.05; CI 0.46–0.83) and TLB
(rho = 0.84; p < 0.05; CI 0.7–0.91). SUVpeak showed a
non-significant (p > 0.05) weak correlation to the ASP
(rho = 0.15; p > 0.05; CI − 0.19–0.45) followed by moderate
correlations to VTV (rho = 0.62; p < 0.05; CI 0.38–0.79)
and TLB (rho = 0.77; p < 0.05; CI 0.59–0.88). PSA blood
level showed non-significant (p > 0.05) weak correlations
to ASP (rho = 0.25; p > 0.05; CI − 0.08–0.53), VTV
(rho = 0.32; p > 0.05; CI − 0.04–0.58), and TLB
(rho = 0.22; p > 0.05; CI − 0.11–0.51). Table 4 summa-
rizes these results.
Fig. 4 Probabilities of a Gleason score for different asphericity values. a The chart plot demonstrates the relative probability for the differentiation
between prostate cancer lesions with Gleason score 6–7 and 8 as well as Gleason score 8 and 9–10. The area left of the black curve indicates the
probability of Gleason 6–7, the area between black and blue curves indicate the probability of an ASP being scored Gleason 8 and the area to
the right of the blue curve indicate the probability for Gleason 9–10. b The lower chart demonstrates cumulative probabilities of a Gleason score
subgroup based on an ASP value containing the same areas beside the curves as described above
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Discussion
This study demonstrated that the ASP in 68Ga-PSMA-
PET could represent a promising quantitative parameter
for an improved non-invasive T-staging of patients with
PC. In the investigated patient collective, patient groups
with different GSc could be discriminated based on the
quantitative assessment of the ASP of the local PC. On
multivariable analysis, it was demonstrated that the ASP
was independently associated with the GSc.
Asphericity for the evaluation of tumor heterogeneity
Aggressiveness of tumor behavior, therapy response and
overall patient survival is known to be associated with
the heterogeneity of the tumor [33, 34]. The parameter
ASP enables the quantification of the associated spatial
irregularities in PET datasets. Previous studies already
investigated the prognostic value of the ASP in certain
types of head and neck cancers and non-small-cell lung
cancer (NSCLC) [15, 19, 21, 35]. The ASP was found
to be an independent predictor of outcome in head
and neck cancer patients undergoing pre-therapeutic
18F-FDG-PET/CT. ASP measurements of the 18F-FDG
uptake also improved the prediction of tumor progression.
These previous studies reported a moderate correlation
between ASP and MTV, while no correlation between
ASP and SUVmax were measured [19, 35]. Additionally, a
recent study demonstrated a significant association be-
tween progression-free survival and overall survival based
on the assessment of the ASP [15].
Comparable results were published for NSCLC, in
which the ASP provided a higher prognostic value for
Table 2 Summary of correlations between in vivo measurements on 68Ga-PSMA PET and ex vivo parameters
GSC D’Amico classification N-stage PI-RADS score
ASP (%) Rho 0.88 0.6 − 0.07 0.26
p value p < 0.05 p < 0.05 p > 0.05 p > 0.05
CI 95% 0.78–0.94 0.32–0.78 − 0.51–0.4 − 0.11–0.57
VTV (cm3) Rho 0.51 0.49 − 0.06 0.33
p value p < 0.05 p < 0.05 p > 0.05 p > 0.05
CI 95% 0.23–0.72 0.17–0.71 − 0.5–0.4 − 0.04–0.62
TLB Rho 0.43 0.38 0 0.3
p value p < 0.05 p < 0.05 p > 0.05 p > 0.05
CI 95% 0.12–0.66 0.04–0.64 − 0.45–0.45 − 0.07–0.6
SUVmax Rho 0.29 0.29 − 0.14 0.22
p value p > 0.05 p > 0.05 p > 0.05 p > 0.05
CI 95% − 0.04–0.56 − 0.06–0.58 − 0.56–0.33 − 0.15–0.54
SUVmean Rho 0.24 0.2 0.13 0.1
p value p > 0.05 p > 0.05 p > 0.05 p > 0.05
CI 95% − 0.09–0.53 − 0.15–0.51 − 0.35–0.55 − 0.27–0.44
SUVpeak Rho 0.3 0.3 − 0.05 0.13
p value p > 0.05 p > 0.05 p > 0.05 p > 0.05
CI 95% − 0.03–0.57 − 0.05–0.58 − 0.49–0.42 − 0.24–0.47
PSA (ng/ml) Rho 0.27 0.15 0.07 0.12
p value p > 0.05 p > 0.05 p > 0.05 p > 0.05
CI 95% − 0.06–0.55 − 0.21–0.47 − 0.4–0.51 − 0.25–0.46
Spearman’s rank correlation method. This table summarizes the associations between the ASP, VTV, TLB, SUVmax, SUVmean, SUVpeak and PSA in the left column
and the GSc, D’Amico classification, N-stage and the PI-RADS score in the upper row using Spearman’s rank correlation method. The closest significant (p < 0.05)
correlations were measured between ASP and GSc followed by a moderate correlation towards the D’Amico classification. A significant (p < 0.05) weak correlation
was seen between VTV and the GSc. Statistically significant correlations (p < 0.05) are highlighted in italics. Abbreviations: ASP asphericity, VTV viable tumor volume,
TLB total lesion binding rate, SUVmax maximum standardized uptake value, SUVmean mean standardized uptake value, SUVpeak peak standardized uptake value,
PSA prostate-specific antigen blood level, GSc Gleason score, PI-RADS prostate imaging reporting and data system
Table 3 Prognostic estimation of Gleason scores using
asphericity, viable tumor volume, and total lesion binding rate
on multivariable analysis
Estimate p value Confidence interval 95%
ASP (%) 0.71 p < 0.05 0.35–1.06
VTV (cm3) 0.36 p < 0.05 0.03–0.69
TLB − 0.02 p > 0.05 − 0.04–0.004
On multivariable analysis using ordinal logistic regression, correlation of the
ASP to GSc was independent against VTV and TLB. A comparable weaker
effect was found for VTV as well. Abbreviations: ASP asphericity, VTV viable
tumor volume, TLB total lesion binding rate
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progression-free survival and overall survival in NSCLC
patients compared to SUVmax, MTV, and another par-
ameter of spatial heterogeneity called solidity [19]. Mod-
erate associations were found between ASP and MTV;
no correlation was measured between SUVmax and ASP
[19]. Additionally, correlations of ASP with histopath-
ology and with the expression of the tumor proliferation
markers KI-67 and epidermal growth factor receptor
(EGFR) in NSCLC were found [35].
These previous studies introduced the ASP as a
promising novel parameter for the non-invasive
characterization of tumors. Additionally, the ASP could
represent a strong predictive parameter regarding the
overall survival in these patient collectives [15, 19].
Evaluation and local staging of prostate cancer by
positron emission tomography
Various radiotracers have been tested for the local sta-
ging of PC. One of these tracers is 18F-FDG. Its accumu-
lation is based on an increased glucose metabolism of
cancer cells due to an overexpression of hexokinase.
18F-FDG uptake was shown to be increased in benign
prostate tissue, including prostate hyperplasia, as well as
in PC cells [11]. Sensitivities of up to 64% for detection
of primary PC were reported [36]. The limited perform-
ance of 18F-FDG for the primary PC diagnosis could be
associated with the relatively low metabolic rate of PC
and the lack of patient selection in these previous stud-
ies [6, 8–10, 37].
A different tracer that demonstrated potential for the
detection of PC is 18F-C. The use of choline-based tracers
is dependent on phosphorylcholine turnover in PC cells.
Most studies, however, reported limited sensitivities, espe-
cially for the primary diagnosis of PC [6, 7, 11]. A further
tracer that was evaluated in this context is 11C-acetate.
Its uptake is a result of an increased lipid synthesis in
tumor cells [38]. Even though its uptake is not limited to
PC cells, this radiotracer was shown to be superior to
18F-FDG for the detection of PC lesions [39]. 11C-MET
and 18F-FDHT have also been evaluated for the staging of
PC. 11C-MET targets the increased amino-acid transport
of methionine for protein synthesis in cancer cells.
18F-FDHT targeting is based on an overexpression of the
androgen receptor. Limitations of these tracers include
the lack of studies regarding their diagnostic value [6].
These previous studies demonstrated that novel more
specific tracers and in vivo parameters are needed for an
improved in vivo detection and characterization of PC.
68Ga-PSMA-PET for the staging of prostate cancer lesions
PSMA is significantly over-expressed in PC cells and over-
expression increases with more advanced tumor stages
[26]. Binding of 68Ga-PSMA-HBED-CC leads to receptor
internalization and tracer accumulation. It is important to
mention that PSMA avid tissue can be found throughout
the body since it is a zinc-dependent exopeptidase with
glutamate carboxypeptidase activity [24]. A recent study
demonstrated promising sensitivity, specificity, and accur-
acy rates of 65.9, 98.9, and 88.5% for the detection of high-
risk PC using 68Ga-PSMA-HBED-CC. However, a reliable
detection can be challenging, as up to 8.4% of all primary
tumors showed no tracer accumulation [13, 40]. Another
recent study investigated the intensity of tracer accumula-
tion in 90 patients using 68Ga-PSMA-HBED-CC. It was
demonstrated that the SUVmax of primary PC was signifi-
cantly higher in GSc > 7 compared to GSc < 7. Addition-
ally, it was shown that a PSA value > 10 ng/ml was an
associated with a significantly higher tracer uptake com-
pared to a PSA value < 10 ng/ml [41]. Other studies fo-
cused on the diagnostic accuracy of recurrent PC using
68Ga-PSMA-HBED-CC. These studies reported sensitiv-
ities and specificities up to 80 and 97% for the detection of
recurrent PC [42–45]. PSA blood levels in biochemical re-
currence correlated with positive findings, even in patients
with low PSA levels (< 1 ng/ml) [14, 43, 46].
Potential of asphericity as a novel diagnostic parameter
in the staging process of patients with
68Ga-PSMA-PET-positive prostate cancer lesions
To the best of our knowledge this was the first study
which combined 68Ga-PSMA-PET with the evaluation of
Table 4 Summary of correlations between asphericity, viable
tumor volume derived from 68Ga-PSMA-PET, TLB, SUVmax,
SUVmean, SUVpeak and the PSA value
ASP (%) VTV (cm3) TLB
SUVmax Rho 0.23 0.58 0.71
p value p > 0.05 p < 0.05 p < 0.05
CI 95% − 0.1–0.51 0.32–0.76 0.5–0.84
SUVmean Rho 0.17 0.68 0.84
p value p > 0.05 p < 0.05 p < 0.05
CI 95% − 0.17–0.47 0.46–0.83 0.7–0.91
SUVpeak Rho 0.15 0.62 0.77
p value p > 0.05 p < 0.05 p < 0.05
CI 95% − 0.19–0.45 0.38–0.79 0.59–0.88
PSA (ng/ml) Rho 0.25 0.32 0.22
p value p > 0.05 p > 0.05 p > 0.05
CI 95% − 0.08–0.53 − 0.04–0.58 − 0.11–0.51
Pearson’s correlation method. This table summarizes the associations between
the ASP, VTV, TLB, SUVmax, SUVmean, SUVpeak and PSA blood level using
Pearson’s correlation method. Neither of the investigated associations presented
a significant correlation (p > 0.05) to the ASP. Significant (p < 0.05) moderate
correlations were demonstrated for VTV and TLB to SUVmax and as expected
also to SUVmean and SUVpeak. PSA did not show a significant correlation
(p > 0.05) to the investigated parameters. Abbreviations: ASP asphericity, VTV
viable tumor volume, TLB total lesion binding rate, SUVmax maximum
standardized uptake value, SUVmean mean standardized uptake value, SUVpeak
peak standardized uptake value, PSA prostate-specific antigen blood level
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the ASP in patients with 68Ga-PSMA-HBED-CC-positive
PC lesions. Previous studies have, as described earlier,
focused on the investigation of the ASP in combination
with other radiotracers, such as 18F-FDG-PET.
The current study demonstrated that the ASP derived
from 68Ga-PSMA-PET enables a distinction between pa-
tient groups with different GSc. Additionally, a correl-
ation of the ASP with the GSc, based on core needle
biopsy, was found. The findings in our studies are in line
with previous studies, in which a correlation between
the ASP and the histopathological staging of NSCLC
was demonstrated [35]. In the current study, no
significant correlation between SUVmax and ASP was
measured [15, 19, 35]. Furthermore, no significant
correlation was found between SUVmax and GSc. In
contrast to previous studies, this study did not demon-
strate a correlation of ASP with the PET tumor volume.
This could be explained by smaller VTV of PC lesions
in comparison to lesions of NSCLC and head and neck
cancer. Our study did not show statistically significant
associations of the ASP to the PI-RADS score.
Further prospective studies and a higher number of
patients are now warranted to investigate the potential
of the ASP in the staging process of PC patients.
This study is limited by its retrospective study design.
Only a relatively small patient cohort with clustered
GSc was investigated. In case of multiple lesions, PC
lesion selection on PET was based on the evaluation of
the MRI data. If the strong radiotracer signal from the
bladder was interfering with an automatic delineation
of the tumor, the tumor delineation was inspected in
axial, coronal, and sagittal planes and VOIs were cor-
rected manually, if necessary. Although several viable
automated algorithms have been described, the VTV is
presently still determined by manual delineation in a
high number of institutions [26, 47–54]. Manual delin-
eation is prone to intra- and interobserver variability
as well as to potentially size- and background-
dependent bias if fixed absolute or relative thresholds
are used.
Conclusions
The ASP in 68Ga-PSMA-PET could represent a promis-
ing parameter for an improved non-invasive T-staging of
patients with PC. Further prospective studies are now
warranted to investigate the potential of the ASP in the
staging process of PC patients.
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